Meeting
2013 Genitourinary Cancers Symposium
Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer.
Authors
Thomas Powles
Barts Cancer Institute, London, United Kingdom
Thomas Powles , Kevin Sharpe , Dan Berney , Irfan Kayani , Rukma Doshi , Grant Duncan Stewart , Andrew Reynolds , Axel Bex , Naveed Sarwar , Simon Chowdhury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 437)
DOI
10.1200/jco.2013.31.6_suppl.437
Abstract #
437
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
First Author: Austin Kalirai
Poster
2017 Genitourinary Cancers Symposium
Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.
First Author: Akhila Ganeshi Wimalasingham
Poster
2024 ASCO Genitourinary Cancers Symposium
Glutamine metabolism and VEGF analysis to elucidate and overcome the mechanism of tyrosine kinase inhibitor resistance in renal cell carcinoma.
First Author: Kento Morozumi
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi